Will Rascan - President & CEO of Nova Mentis Life Science Corp.Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to be granted Orphan Drug designation for the use of psilocybin in the treatment of Fragile X by both the EMA & FDA. Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS).
-
Iterim CeoAlerio Gold Corp.Canada -
President & CeoNova Mentis Life Science Corp. (Nova:Cse) Jul 2020 - PresentVancouver, British Columbia, Canada
-
President & CeoLiberty Leaf Holdings Ltd. Lib:Cse May 2012 - Jul 2020Vancouver, Canada Areahttp://www.libleaf.com
-
Sr. Investment AdvisorNorthern Securities Dec 2008 - May 2012Vancouver
-
Investment AdvisorJennings Capital Inc. 2005 - 2008Vancouver
-
Investment AdvisorScotiamcleod/Research Capital/Blackmont Capital 1997 - 2005Vancouver, Canada Area -
Vp, Institutional Money Market SalesScotiamcleod 1993 - 1997Vancouver, Canada Area
Will Rascan Skills
Frequently Asked Questions about Will Rascan
What company does Will Rascan work for?
Will Rascan works for Alerio Gold Corp.
What is Will Rascan's role at the current company?
Will Rascan's current role is Iterim CEO.
What skills is Will Rascan known for?
Will Rascan has skills like Venture Capital, Capital Markets, Private Equity, Equities, Investments, Due Diligence, Investor Relations, Trading, Business Development, Sales, Management, Entrepreneurship.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial